Ipamorelin GHSR-1a Research: Endocrine Cell Models and Receptor Pharmacology
Ipamorelin is a research compound studied in cell-based assay formats for its selective GHSR-1a (class A GPCR) Gq/calcium mobilisation. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
Receptor Pharmacology and Mechanism of Action
GHSR-1a Binding Characteristics
Ipamorelin acts via selective GHSR-1a (class A GPCR) Gq/calcium mobilisation. Competitive radioligand binding assays demonstrate high-affinity binding to the growth hormone secretagogue receptor with dissociation constants (Kd) in the nanomolar range. Saturation binding experiments in recombinant cell lines expressing human GHSR-1a reveal specific binding parameters distinct from endogenous ghrelin, indicating unique molecular recognition patterns at the orthosteric binding site.
Structure-activity relationship studies using various peptide analogues show that the D-phenylalanine residue at position 3 and the lysine at position 6 are critical for receptor binding affinity. Competitive displacement assays with reference compounds confirm selective binding to GHSR-1a over related G-protein coupled receptors, including melanocortin and orexin receptor subtypes.
G-Protein Coupling and Signal Transduction
Following receptor binding, ipamorelin activates Gq/11 signalling pathways through conformational changes in the GHSR-1a receptor structure. Calcium mobilisation assays in engineered cell lines demonstrate robust intracellular calcium flux with EC50 values typically ranging from 0.1-1.0 μM depending on the specific cell model employed. Time-course experiments reveal rapid onset kinetics with peak calcium responses occurring within 30-60 seconds of compound addition.
Phospholipase C activation downstream of Gq coupling leads to inositol 1,4,5-trisphosphate (IP3) generation and diacylglycerol (DAG) formation. IP3 accumulation assays in GHSR-1a-transfected cells show dose-dependent responses that parallel calcium mobilisation data, confirming engagement of the classical Gq/PLC/IP3 signalling cascade.
In Vitro Cell Model Systems
Recombinant Expression Systems
HEK293 and CHO cell lines stably transfected with human GHSR-1a serve as primary model systems for ipamorelin pharmacological characterisation. These recombinant systems allow precise control of receptor expression levels and elimination of confounding variables from endogenous receptor populations. Flow cytometry analysis confirms consistent receptor surface expression across passage numbers, ensuring reproducible assay conditions.
Transient transfection protocols using various GHSR-1a constructs, including fluorescently-tagged variants, enable real-time monitoring of receptor trafficking and internalisation dynamics following agonist exposure. Confocal microscopy studies reveal receptor endocytosis patterns consistent with typical GPCR desensitisation mechanisms.
Endocrine Cell Models
Primary pituitary cell cultures and immortalised somatotroph cell lines provide physiologically relevant models for studying ipamorelin activity in native cellular contexts. These systems express endogenous GHSR-1a alongside the complete cellular machinery for hormone synthesis and secretion processes.
Enzyme-linked immunosorbent assays (ELISA) in these cell models demonstrate concentration-dependent responses to ipamorelin treatment, with optimal activity observed in serum-free culture conditions. Time-course experiments reveal biphasic response patterns, with early peak responses followed by sustained elevation periods extending several hours post-treatment.
Enzyme Kinetics and Binding Studies
Kinetic Analysis Parameters
Kinetic binding studies utilise radiolabelled ghrelin as a tracer ligand to determine association and dissociation rate constants for ipamorelin-GHSR-1a interactions. Association experiments reveal rapid binding kinetics with kon rates of approximately 10^6 M^-1s^-1. Dissociation studies demonstrate relatively slow off-rates, contributing to the compound's high binding affinity profile.
Competition kinetic experiments compare ipamorelin binding parameters with reference agonists and antagonists. These studies confirm competitive binding behaviour and provide Hill coefficients indicating single-site binding interactions without evidence of receptor cooperativity.
Functional Selectivity Assessment
Pathway-selective assays examine potential biased signalling properties of ipamorelin compared to endogenous ghrelin. Beta-arrestin recruitment assays using bioluminescence resonance energy transfer (BRET) technology reveal differential signalling bias, with ipamorelin showing preferential G-protein activation over arrestin recruitment pathways.
Research Summary
In vitro research demonstrates that ipamorelin functions as a selective GHSR-1a agonist with nanomolar binding affinity and robust Gq/calcium signalling activation. Cell-based assays in both recombinant and endocrine model systems confirm consistent pharmacological activity across multiple experimental platforms. Kinetic studies reveal favourable binding characteristics with rapid association and slow dissociation kinetics. The compound exhibits functional selectivity for G-protein pathways over arrestin recruitment, distinguishing its signalling profile from endogenous receptor ligands. These pharmacological properties make ipamorelin a valuable research tool for investigating GHSR-1a receptor biology and downstream signalling mechanisms in controlled laboratory environments.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML